Development of a 99mTc-labeled tetrazine for pretargeted SPECT imaging using an alendronic acid-based bone targeting model
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0300466 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Lennart Bohrmann und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada. Hauptthemen laut MEDLINE: Tomography, X-Ray Computed, Heterocyclic Compounds. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Lundbeck Foundation, Natural Sciences and Engineering Research Council of Canada.
Abstract (Originalsprache)
Pretargeting, which is the separation of target accumulation and the administration of a secondary imaging agent into two sequential steps, offers the potential to improve image contrast and reduce radiation burden for nuclear imaging. In recent years, the tetrazine ligation has emerged as a promising approach to facilitate covalent pretargeted imaging due to its unprecedented kinetics and bioorthogonality. Pretargeted bone imaging with TCO-modified alendronic acid (Aln-TCO) is an attractive model that allows the evaluation of tetrazines in healthy animals without the need for complex disease models or targeting regimens. Recent structure-activity relationship studies of tetrazines evaluated important parameters for the design of potent tetrazine-radiotracers for pretargeted imaging. However, limited information is available for 99m Tc-labeled tetrazines. In this study, four tetrazines intended for labeling with fac -[ 99m Tc(OH 2 ) 3 (CO) 3 ] + were synthesized and evaluated using an Aln-TCO mouse model. 3,6-bis(2-pyridyl)-1,2,4,5-Tz without additional linker showed higher pretargeted bone uptake and less background activity compared to the same scaffold with a PEG 8 linker or 3-phenyl-1,2,4,5-Tz-based compounds. Additionally, improved bone/blood ratios were observed in pretargeted animals compared to animals receiving directly labeled Aln-TCO. The results of this study implicate 3,6-bis(2-pyridyl)-1,2,4,5-Tz as a promising scaffold for potential 99m Tc-labeled tetrazines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.
- Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken, Copenhagen, Denmark.
- Department of Drug Design and Pharmacology, Faculty of Health and Medicinal Sciences, University of Copenhagen, Universitetsparken, Copenhagen, Denmark.
- Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, Blegdamsvej, Copenhagen, Denmark.
ORCID-Profile: Cristina Rodríguez-Rodríguez, Urs O Häfeli
Förderung
- Lundbeck Foundation
- Natural Sciences and Engineering Research Council of Canada
Zitieren
APA
Bohrmann, L., Poulie, C. B. M., Rodríguez-Rodríguez, C., Karagiozov, S., Saatchi, K., Herth, M. M., & Häfeli, U. O. (2024). Development of a 99mTc-labeled tetrazine for pretargeted SPECT imaging using an alendronic acid-based bone targeting model. PLOS ONE. https://doi.org/10.1371/journal.pone.0300466
Vancouver
Bohrmann L, Poulie CBM, Rodríguez-Rodríguez C, Karagiozov S, Saatchi K, Herth MM, et al. Development of a 99mTc-labeled tetrazine for pretargeted SPECT imaging using an alendronic acid-based bone targeting model. PLOS ONE. 2024. doi:10.1371/journal.pone.0300466
BibTeX
@article{Bohrmann2024,
author = {Bohrmann, Lennart and Poulie, Christian B M and Rodríguez-Rodríguez, Cristina and Karagiozov, Stoyan and Saatchi, Katayoun and Herth, Matthias M and Häfeli, Urs O},
title = {Development of a 99mTc-labeled tetrazine for pretargeted SPECT imaging using an alendronic acid-based bone targeting model},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0300466}
}
EUVIMED